Effect of Early Administration of TXA in Adult Hip Fractures

Last updated: September 14, 2021
Sponsor: Ascension Genesys Hospital
Overall Status: Active - Recruiting

Phase

2/3

Condition

Osteoporosis

Hemorrhage

Treatment

N/A

Clinical Study ID

NCT05047133
1722787-1
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. All adult (18 years old or older) hip fracture patients presenting with an acutehip fracture and undergoing operative fixation

Exclusion

Exclusion Criteria:

  1. Polytrauma patients
  2. Previous operation on the ipsilateral hip
  3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  4. Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, CardiacStents, or Myocardial Infarction (MI)
  5. History of seizure disorder
  6. Patients on birth control
  7. Pregnant Women
  8. Prisoners
  9. Active thromboembolic disease (DVT/PE, MI, Stroke)

Study Design

Total Participants: 170
Study Start date:
September 01, 2021
Estimated Completion Date:
July 01, 2022

Connect with a study center

  • Ascension Genesys Hospital

    Grand Blanc, Michigan 48439
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.